FutureChem Starts Dosing of Radioactive Anticancer Drug 'FC705' in US Phase 2a Trial

FutureChem, a specialist company in radiopharmaceuticals, announced on the 13th that the prostate cancer treatment FC705, targeting castration-resistant metastatic patients, has begun the first patient dosing in the US Phase 2a clinical trial.

FutureChem CI
Photo by FutureChem

Prostate cancer is a representative male cancer with the highest incidence rate among men in the US, with 270,000 new cases occurring annually. FutureChem's FC705 is being developed as a 'best-in-class' new drug for prostate cancer treatment, aiming to maximize therapeutic effects with a high tumor uptake rate compared to competing drugs while minimizing side effects such as radiation exposure by using half the dosage.

The US clinical trial of FC705 is being conducted at five centers, including the University of Maryland Medical Center. In the previous Phase 1 trial, the objective response rate (ORR) and disease control rate (DCR), which indicate the proportion of patients responding to treatment, were both 100%. A decrease in prostate-specific antigen (PSA) was confirmed in all patients participating in the trial. In the US Phase 2a trial, a dose of 100 millicuries (mCi) (3700 megabecquerels (Mbq)) will be repeatedly administered to 20 patients. Through this, the safety and efficacy of the drug for metastatic castration-resistant prostate cancer patients will be evaluated.

This content was produced with the assistance of AI translation services.